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Release of interleukin-6 in acute myocardial infarction: 
apparent difference between myocardial necrosis and 
stunning
W.K. Lagrand1, F. Nijland1, C.E. Hack1’2, 0. Kamp1, F.W.A. Verheugt1,
C.A. Visser1. 1 Free University Hospital, 2 Central Laboratory of The Nether­
lands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
Background: Elevated plasma levels of C-Reactive Protein (CRP) and lnter- 
leukin-6 (IL-6; the cytokine mainly responsible for CRP synthesis by the liver) 
have been demonstrated in patients with acute myocardial infarction (AMI). 
Piasma CRP has been correlated with infarct size, whilst plasma IL-6 has been 
associated with myocardial stunning.
Methods: To assess whether CRP and IL-6 are related to infarct size, my­
ocardial stunning or both, we measured the cumulative release of CRP and fL-6 
during the first 48 hours in 44 patients with first AMI. Infarct size was assessed 
enzymatically (72-hours cumulative LDH release) and by 2D-echocardiogra- 
phy using wall motion score (WMS) at admission and at 3 months. Myocardial 
stunning was defined as change in WMS and number of segments showing 
recovery from baseline to 3-months foiiow-up. Patients were divided in 2 groups 
of 22 patients by median release values of CRP (66 mg/L) and IL-6 (208 ¿¿g/L). 
Results:




P <208 >208 P
Mean WMS (admission) 7.1 8.5 NS 7.3 8.3 NS
Mean WMS (3 months) 3.2 6.5 0.02 3.2 6.6 0,01
Change WMS (adm.-3 months) 3.9 2.0 0.04 4.1 1.7 0.01
Recovery (mean # segments) 3.0 2.3 NS 3.3 2.1 0.03
Furthermore, IL-6 release correlated with cumulative LDH (r = 0.38; p » 
0.01), CRP release (r = 0.47; p = 0.001) and 3-months WMS (r = 0.44; p = 
0.003). CRP release correlated with cumulative LDH (r = 0.40; p = 0.007) and 
3-months WMS (r = 0.49; p = 0.001).
Conclusion: IL-6 and CRP release in first AMI are positively correlated with 
infarct size. Myocardial stunning is more apparent in both the low IL-6 and CRP 
release groups.
Decreased levels of beta-endorphin in circulating 
mononuclear leukocytes from patients with acute 
myocardial infarction
Thomas Buratti, Christoph Pechlaner, Michael Joannidis, Paola Sacerdote1, 
Alberto E. Panerai1, Christian J. Wiedermann. Intensive Care Unit,
Department of Medicine, University of Innsbruck, Austria, 1 Department of 
Pharmacology, University of Milan, Milan, Italy
Objetives: Beta-adrenergic stimulation and interleukin-1 activate lymphocytes 
to release opioids that subsequently occupy opioid receptors on sensory nerves 
and result in antinociception. Since both catecholamines and cytokines are el­
evated in acute coronary syndromes, we investigated levels of immunoreactive 
beta-endorphin in peripheral blood mononuclear cells from patients with acute 
myocardial infarction.
Methods: From 11 patients with acute myocardial infarction forearm venous 
blood samples were taken on admission and after 6, 12, 24, and 48 hours for 
routine laboratory measurements and peripheral blood mononuclear leukocyte 
preparations. Mononuclear leukocytes were counted, pelleted and homoge­
nized; beta-endorphin was measured in supernatants by radioimmunoassay.
Results: Concentrations of immunoreactive beta-endorphin in mononuclear 
leukocytes at admission were 30.2 ± 6 .9  pg/106 celts and decreased signif­
icantly to 6.9 ±  1.9 pg/106 cells after 48 hours (p < 0.05). Concomitantly 
plasma levels of C-reactive protein gradually increased from the normal range 
at admission to 12.4 ± 1.74 mg/dl at 48 hours. An inverse correlation was 
found between cell-associated immunoreactive beta-endorphin and C-reactive 
protein measurements in serum (p < 0.05).
Conclusion: Decreased mononuclear leukocyte-associated levels of im­
munoreactive beta-endorphin in acute myocardial infarction may be due to its 
release after stimulation with stress and acute-phase reactants. Release of 
beta-endorphin from immune cells at the site of myocardial injury may affect 
peripheral nociception as well as endothelial and inflammatory cell functions.
Increase of IL-1 Ra during the first two days of 
hospitalization is associated with increased risk of 
in-hospital coronary events
G. Liuzzo, G. Fantuzzi, L.M. Biasucci, C.A. Dinarello, A. Maseri. Cardiology, 
Catholic University, Rome, Italy, infectious Diseases, Denver, CO, USA
In unstable angina increased levels of acute phase reactants and interleukin-6 
have been found on admission and are associated with an increased risk of 
in-hospital coronary events. To assess whether levels of other cytokines are 
associated with outcome, we measured IL-1 Ra levels in 43 patients with severe 
unstable angina, after admission and following appropriate medical therapy.
Blood samples were taken on admission, and at 24 and 48 hours, thereafter.
Results: IL-1Ra data are presented as median and range. Patients were 
grouped according to the presence of in-hospital events (death, myocardial 
infarction or refractory angina): 26 patients had in-hospital events (G1) and 
17 had an uneventful course (G2), In G1, IL-1Ra was 0.347 (0.058-0.854) 
ng/ml on admission and rose to 0,426 (0.09-1.234) ng/ml at 48 hours (P = 
0.011). Conversely, in G2, IL-1 ra on admission was 0.184 (0.012-1.368) ng/mi 
(P = 0.009 vs G1) and did not change significantly at 48 hours (0.176, range 
0.006-0.816).
Conclusion: Our study demonstrates that levels of IL-1 Ra, a reliable marker 
of IL-1 p andTNF-a production, are elevated on admission, and increase further 
at 48 hours in spite of full medical therapy, in patients with unstable angina and 
En-hospitai events. Conversely, patients with an uneventful in-hospital course 
have significantly lower levels of IL-1 ra. Our data may open new avenues to 
novel therapeutic approaches in unstable angina.
Can C-reactive protein or troponins T and I predict 
outcome in patients with intractable unstable angina?
N. Curzen, D. Patel, M. Kemp1, J. Hooper1, C. Knight, C, Wright, D. Clarke, 
K. Fox. Department of Cardiology, Royal Brompton Hospital, London, UK,
1 Department of Clinical Biochemistry, Royal Brompton Hospital, London, UK
C-reactive protein, a sensitive marker of inflammation, has previously been 
reported to be elevated in unstable angina. Recently, levels of both troponin I 
and T, which are sensitive and specific markers of myocardial injury, have been 
shown to correlate with outcome In acute coronary syndromes. We measured 
these 3 markers in 72 patients (54 male; mean age 62.9 yrs (range 36.0-72.4)) 
transferred to this centre with refractory chest pain in whom acute myocardial 
infarction was excluded by absence of > twofold rise in creatine kinase. 
Presence of transient myocardial ischaemia (TMI) (detected by continuous 
ST segment monitoring) and coronary anatomy (angiographic analysis by two 
blinded observers) were also assessed.
Results: Median levels for CRP, troponin T and troponin I were 8.7 mg/dl 
(4,8-203,9), 0.0 /xg/L (0-2.51), 0.05 /ug/L (0-7.8) respectively. 7 (10%) patients 
had normal coronaries and 14, 20, 31 had 1,2, or 3 vessel coronary disease, 
respectively. 19 (26%) had TMI, 33 (46%) had complex lesion morphology and 
6 (8%) had intracoronary thrombus. Of the 3 markers, troponin T alone was 
higher in patients with multivessel disease (p < 0.05) and those with TMI (p < 
0.05), but there was no significant relationship between CRP, troponin T or I 
and lesion morphology or thrombus.
Conclusion: In patients transferred to a tertiary centre with intractable chest 
pain, CRP and troponin I are not predictive of TMI or lesion morphology, both 
of which are surrogate markers of outcome. Troponin T is, however, elevated 
In those patients with multivessel disease and also those with TMI.
Vascular endothelial growth factor mRNA synthesis by 
peripheral blood mononuclear ceils in patients with 
acute myocardial infarction
Y. Sasaki, A. Kawamoto, M, Iwano, E. Takase, H. Kawata, S. Tsujimura,
Y. Akai, T. Hashimoto, K. Dohi. First Department of Internal Medicine, Nara 
Medical University, Kashihara, Japan
Vascular endothelial growth factor (VEGF) Is an angiogenic glycoprotein that is 
upregulated In cardiac myocyte subjected to ischemia, Serum levels of VEGF 
are reportedly elevated in the subacute phase of acute myocardial infarction 
(AMI). However, there is no direct evidence that VEGF mRNA Is expressed in 
patients with AMI. To investigate whether VEGF mRNA is expressed in AMI, 
we measured levels of VEGF mRNA in peripheral blood mononuclear cells 
(PBMC) obtained from patients with AMI using competitive polymerase chain 
reaction (PCR).
Methods: Fifteen patients with AMI and 15 healthy controls were enrolled 
in this study. PBMC were isolated from all patients on day 14 after onset, 
and from all controls. Total RNA was extracted from PBMC and reverse 
transcribed into cDNA. We performed competitive PCR by co-ampllfying serial 
dilutions of GAPDH mutant templates containing a unique Eco Rl site. Next, 
to measure VEGF cDNA semiquantitatively in the samples containing identical 
amount of GAPDH, we performed competitive PCR similarly by co-amplifying 
serial dilutions of VEGF mutant templates containing a unique Eco RV site. 
We measured VEGF mRNA by Southern blot and densitometry. Sera were 
also obtained from the same patients on day 14 after onset, and the serum 
concentration of VEGF was measured by ELISA method.
Results: Higher levels of VEGF mRNA in the PBMC were observed in the 
AMI patients (3.0 ±  1.5 fg/pg GAPDH) than in healthy controls (1.8 ± 0.4 fg/pg 
GAPDH) (p < 0.05). Serum levels of VEGF were significantly correlated with 
the amount of VEGF mRNA in the PBMC (p < 0.05).
Conclusions: Levels of VEGF mRNA in PBMC were elevated in the subacute 
phase of AMI and significantly correlated with serum VEGF concentration. Re­
sults suggest that VEGF in PBMC is overexpressed in response to some signals 
during the subacute phase of AMI for the purpose of angiogenesis and healing.
